Veterans and military families chasing weight-loss drugs like Wegovy and Zepbound are running into a coverage maze that shifted hard in 2025, cutting off some retirees while leaving others with a path forward.
Quick Take
- TRICARE covers Ozempic and Mounjaro only for type 2 diabetes, not for weight loss.
- Wegovy and Zepbound are covered for weight management, but only under specific TRICARE plans with prior approval.
- TRICARE for Life and direct-care-only beneficiaries lost weight-loss drug coverage starting August 31, 2025.
- VA and CHAMPVA coverage rules mostly tie GLP-1 drugs to diabetes, sleep apnea, or heart risk, not general weight loss.
- Confusing, scattered rules across TRICARE, VA, and CHAMPVA make it hard for veterans to know what they can actually get.
Diabetes Drugs Get Easier Approval
TRICARE’s own pharmacy website says it plainly: Ozempic, Mounjaro, Trulicity, and Victoza are covered to treat type 2 diabetes. These drugs still need prior authorization, but the path is simpler because the Food and Drug Administration approved them for blood sugar control. Veterans and service members with a diabetes diagnosis face fewer hoops than those seeking the same drugs for weight loss.
Weight-Loss Coverage Comes With Strings Attached
Wegovy and Zepbound are FDA-approved for weight loss, and TRICARE does cover them, but only for people enrolled in certain plans. Those include TRICARE Prime, TRICARE Select, TRICARE Young Adult, and a few others. Beneficiaries must also pass prior authorization and often try cheaper drugs first, a process called step therapy, before insurance pays out.
The gap between diabetes coverage and weight-loss coverage causes real confusion. Some online guides claim Ozempic is never covered for weight loss under any circumstance, which is true only when it’s prescribed off-label. TRICARE’s contractor, Express Scripts, confirms weight-loss drugs are “covered for beneficiaries with TRICARE Prime and TRICARE Select” specifically, not for everyone.
Retirees Lost Access Last Summer
The Defense Health Agency announced a major cut in August 2025. People on TRICARE for Life, mostly Medicare-eligible military retirees, lost weight-loss drug coverage starting August 31, 2025. Civilians who only use military hospitals and clinics for care also lost access. The agency said the change was about controlling costs, not medical necessity, according to reporting at the time.
That cutoff hit older veterans and retirees hardest, since many rely on TRICARE for Life as their main health plan after leaving military hospitals behind. Advocacy group Military Officers Association of America has tracked the fallout, noting that even beneficiaries who remain covered still face a $38 copay per 90-day supply once approved.
VA and CHAMPVA Rules Follow a Similar Pattern
The VA’s CHAMPVA program, which serves some veterans’ dependents, covers GLP-1 drugs only for specific FDA-approved reasons. Those include type 2 diabetes, obstructive sleep apnea for Zepbound, and prevention of major heart problems in certain patients. Weight loss alone, without one of those diagnoses, generally does not qualify a person for coverage under CHAMPVA’s published rules.
Reporting on the broader VA health system suggests weight-loss access requires documented attempts at cheaper treatments first, along with participation in structured weight-management programs and meeting body mass index thresholds. But no VA-wide formulary document in the public record spells out routine obesity coverage the way CHAMPVA’s rules do for diabetes and sleep apnea.
Why the Confusion Matters
Millions of veterans and military families depend on these programs for basic care, yet the rules split across TRICARE, VA, and CHAMPVA websites, contractor pages, and news releases. That fragmentation makes it easy for both patients and outside commentators to misread what’s actually covered, fueling frustration that already runs high over rising drug costs and shifting federal health benefits nationwide.
The bottom line for veterans and families is straightforward but frustrating: coverage depends heavily on diagnosis, plan type, and paperwork, not just whether a drug works. Anyone seeking Wegovy, Zepbound, Ozempic, or Mounjaro should check their specific plan’s rules directly rather than assume blanket coverage or blanket denial applies to their situation.
Sources:
peakwellnessva.com, formblends.com, trimrx.com, va.gov, moaa.org
© bingeworthynews.com 2026. All rights reserved.
